B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency
Status: | Withdrawn |
---|---|
Conditions: | Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - 89 |
Updated: | 6/20/2018 |
Start Date: | March 2012 |
End Date: | March 2016 |
B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) Form of Mevalonate Kinase Deficiency (MKD)
The hyper IgD syndrome (HIDS) is an inflammatory disease caused by mevalonate kinase
deficiency. There is no cure, and available treatments of HIDS febrile episodes have shown
limited clinical efficacy. The development of effective interventions for HIDS is limited by
our poor understanding of the disease. The goal of the study is to better characterize the
inflammatory response during HIDS episodes and to determine the relationship between this
response and blood and urine markers of mevalonate kinase deficiency. This knowledge will
help us learn more about the cause of the disease and should lead to the identification of
new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic
trials.
The primary hypothesis is that the costimulatory B7 glycoprotein abnormalities identified in
the murine MKD model will be recapitulated in sera obtained from human HIDS patients, either
before, during or after febrile episodes. The secondary hypothesis is that B7 glycoprotein
molecule levels will correlate with clinical symptomatic severity score, other known
biomarkers of HIDS, markers of inflammation and or markers of isoprenoid metabolism.
deficiency. There is no cure, and available treatments of HIDS febrile episodes have shown
limited clinical efficacy. The development of effective interventions for HIDS is limited by
our poor understanding of the disease. The goal of the study is to better characterize the
inflammatory response during HIDS episodes and to determine the relationship between this
response and blood and urine markers of mevalonate kinase deficiency. This knowledge will
help us learn more about the cause of the disease and should lead to the identification of
new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic
trials.
The primary hypothesis is that the costimulatory B7 glycoprotein abnormalities identified in
the murine MKD model will be recapitulated in sera obtained from human HIDS patients, either
before, during or after febrile episodes. The secondary hypothesis is that B7 glycoprotein
molecule levels will correlate with clinical symptomatic severity score, other known
biomarkers of HIDS, markers of inflammation and or markers of isoprenoid metabolism.
Inclusion Criteria:
- any race or ethnicity
- diagnosed with HIDS
Exclusion Criteria:
- parents' inability to donate blood
- currently having cancer, renal failure, diabetes, liver disease, thyroid diseases,
major infectious diseases or immunodeficiency
- pregnancy
- inability to provide consent
We found this trial at
4
sites
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
Click here to add this to my saved trials